ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Moxifloxacin

Also written as “Avelox (Moxifloxacin, BAY12-8039)”, “Moxifloxacin (Avelox, BAY12-8039)” and “moxifloxacin”.

Its studies are mostly in Cataract · Conjunctivitis, Bacterial · Otitis Media · Sinusitis · Community-Acquired Pneumonia, led by 14 companies.

Drug pageMoxifloxacin: every studyMany companies study it; this page follows only the 55 they lead. All 201 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jun 26, 200755 company-led studies, 2 open or runningNext primary completion: Oct 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer200 open or runningphase 4since Jun 26, 2007Nov 21, 2006none ahead
Alconits history only140 open or runningphase 4since Apr 4, 2006Apr 4, 2006none ahead
Pfizerits history only40 open or runningphase 1since Jul 10, 2007Jul 10, 2007none ahead
GlaxoSmithKlineits history only30 open or runningphase 1since Oct 8, 2009Oct 8, 2009none ahead
Da Volterraits history only20 open or runningphase 1since Jun 25, 2014Jun 25, 2014none ahead
Laboratorios Sophia S.A de C.V.its history only21 open or runningphase 3since Jul 30, 2025Apr 9, 2024none ahead
Richmond Pharmacologyits history only20 open or runningphase 1since Jun 19, 2012Jun 19, 2012none ahead
Viatrisits history only20 open or runningphase 1since Sep 7, 2005Sep 7, 2005none ahead
Adapt Produtos Oftalmológicos Ltda.its history only10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
Dr. Reddy's Laboratoriesits history only10 open or runningphase 1since Dec 18, 2014Dec 18, 2014none ahead

Also a collaborator on its studies: AbbVie, Parexel, Bristol-Myers Squibb, Topical Solutions and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 21, 2006.

  1. May 14, 2007Phase 3 study in Lung DiseasesNCT00473460 · 1,404 enrolled · United States, Andorra, Argentina and more
  2. Jun 26, 2007Phase 4 study in SinusitisNCT00493038 · 293 enrolled · Italy
  3. Jun 26, 20072 phase 3 studiesNCT00492726, NCT00492024
  4. Apr 4, 20083 phase 4 studiesNCT00656747, NCT00665327, NCT00668304
  5. May 21, 2008Phase 3 study in Pelvic Inflammatory DiseaseNCT00683865 · 749 enrolled · Denmark, Finland, France and more
  6. Jul 16, 2008Phase 3 study in PneumoniaNCT00717561 · 60 enrolled · Italy
  7. Oct 7, 2008Phase 3 study in Intraabdominal InfectionsNCT00769171 · 364 enrolled · China, Hong Kong, Indonesia and more
  8. Jan 23, 2009Phase 3 study in Communicable DiseasesNCT00828971 · 16 enrolled · Italy
  9. Nov 12, 2009Phase 1 study in QTc EvaluationNCT01014247 · 56 enrolled · Australia, Germany, Singapore and more
  10. Jan 8, 2010Phase 3 study in Pneumonia, AspirationNCT01045902 · 139 enrolled · Germany
  11. Jan 13, 2010Phase 1 study in InfectionsNCT01049022 · 31 enrolled · United States
  12. Feb 15, 2010Phase 3 study in Intraabdominal InfectionsNCT01069900 · 458 enrolled · United States, Argentina, Bulgaria and more
  13. Feb 22, 2010Phase 1 study in HealthyNCT01073891 · 24 enrolled · Germany
  14. Jul 28, 2022Phase 1 study in Multiple Endocrine Neoplasia Type 1NCT05481528 · 51 enrolled · Germany

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Topoisomerase IV inhibitor; Bacterial DNA gyrase inhibitor”ChEMBL 37, by rule

Studies

All 20 Bayer leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05481528Multiple Endocrine Neoplasia Type 1 · Germany1CompletedFeb 7, 202351
NCT01073891Healthy · Germany1CompletedNov 201024
NCT01069900Intraabdominal Infections · United States, Argentina, Bulgaria and more3CompletedJan 21, 2015458
NCT01049022Infections · United States1CompletedDec 201231
NCT01045902Pneumonia, Aspiration · Germany3Completed139
NCT01014247QTc Evaluation · Australia, Germany, Singapore and more1CompletedJun 201056
NCT00828971Communicable Diseases · Italy3CompletedSep 200916
NCT00769171Intraabdominal Infections · China, Hong Kong, Indonesia and more3CompletedDec 2006364
NCT00717561Pneumonia · Italy3CompletedMay 200960
NCT00683865Pelvic Inflammatory Disease · Denmark, Finland, France and more3CompletedOct 2004749
NCT00668304Maxillary Sinusitis · United States, Argentina4Completed192
NCT00665327Pneumonia · United States, Puerto Rico4CompletedApr 2004401
NCT00656747Bronchitis, Chronic · Andorra, Argentina, Australia and more4CompletedDec 20101,372
NCT00493038Sinusitis · Italy4TerminatedJan 2008293
NCT00492726Infections · Argentina, Belgium, Bulgaria and more3CompletedFeb 2009804
NCT00492024Sinusitis · United States3CompletedMar 2008374
NCT00473460Lung Diseases · United States, Andorra, Argentina and more3CompletedJan 20071,404
NCT00453349Pelvic Inflammatory Disease · China, Indonesia, Korea, Republic of and more3CompletedMay 2008460
NCT00431678Pneumonia · Argentina, Belgium, Chile and more3CompletedJul 2005738
NCT00402727Abscess · Austria, Belgium, Bulgaria and more3CompletedJun 2008813

How it is read

Names in the registry

  • “Moxifloxacin”, 32 entries
  • “Avelox (Moxifloxacin, BAY12-8039)”, 11 entries
  • “Moxifloxacin (Avelox, BAY12-8039)”, 9 entries
  • “moxifloxacin”, 6 entries
  • “Moxidex otic solution”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.